2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Serologic Tests, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Checkpoint Inhibitor, Immunotherapy, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1825 Immune checkpoint inhibitors in Hodgkin lymphoma among people with HIV: A real-world matched analysis of safety, infections, and secondary malignancies using trinetx

Dhruv Dhiren Mistry, MBBS, Maria J. Fernandez-Turizo, MD2, Maya deepti Srinivasan, MD, MSc3, John Mark L Sloan Jr, MD4
1 Boston Medical Center, Boston, Massachusetts, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Boston Medical Center, Boston, Massachusetts, United States, Boston Medical Center, Boston, Massachusetts, United States
4 Boston Medical Center, Boston, Massachusetts, United States

Introduction: The use of Immune checkpoint inhibitors (ICIs) for the management of classical Hodgkin Lymphoma (cHL) represents a paradigm shift as they have improved disease control and decreased immediate and late toxicities. HIV independently confers cytopenias and infectious risk along with chronic immune activation which might alter immune-related effects of PD-1 blockade. However, pivotal clinical trials have had poor representation of people with HIV (PWH). As ICIs become standard therapy in cHL, real-world safety data in PWH is scarce. We compared safety, infectious and secondary malignancy outcomes after ICI therapy in cHL with and without HIV. Methods: Using the TriNetX Global Collaborative Network, we retrospectively identified patients with cHL who received at least one dose of Nivolumab or Pembrolizumab, treated from January 1, 2015 onwards. We stratified them by HIV status (HL+ICI+HIV, n=100 vs. HL+ICI w/o HIV, n=3013). Cohorts were matched 1:1 by propensity score on age, sex, race and chronic comorbidities (primary hypertension, chronic kidney disease, type 2 diabetes mellitus), and baseline cell counts (RBCs, WBCs and platelets). Safety was evaluated through 5 years from index date, using severe cytopenias (primary outcome, defined by CTCAE Grade 3/4 or pancytopenia), supportive care measures (G-CSF i.e. Granulocyte Colony-Stimulating Factor, RBC or platelet transfusions), opportunistic infections and immune-related adverse event (irAEs). Second primary malignancies (SPMs) were followed through 10 years to account for their longer latency. Risk ratios (RRs) were used for cumulative incidence, and hazard ratios (HRs) derived from Cox proportion models. Results: Of 2,058 PWH with cHL identified in the database, 808 (39.3%) had documented antineoplastic treatment, of whom only 12.4% received ICI therapy. After matching, two cohorts of n=98 (each arm) were analysed, with a median follow-up of 1147 days in the HIV cohort and 915 days in the non-HIV cohort. The matched HIV cohort had a median age of 46 years, was predominantly male (71.7%), and racially diverse (54.3% non-Hispanic whites, 27.2% African Americans, 10.9% Hispanics and 10.9% Asians), with a median baseline CD4 count of 266 cells/µL. For the primary outcome, the HIV cohort showed a non-significant trend toward higher rates of severe cytopenias (80.3% vs. 68.4%; RR 1.17, p=0.096), occurring slightly earlier at a median of 130 vs. 196 days (HR 1.42, 95% CI 0.98–2.06, p=0.065). Similarly, slightly increased need for G-CSF (68.1% vs. 64.9%; HR 1.12, p=0.521) and transfusions interventions (37.4% vs. 28.0%; HR 1.29, p=0.325) were observed in the HIV group. Regarding infection outcomes, opportunistic infections occurred in 24% vs. 14.1% (HR 1.79, p=0.102), febrile neutropenia in 65.7% vs. 58.2% (HR 1.25, p=0.283), viral reactivations in 21.5% vs. 13% (HR 1.7, p=0.152), and sepsis in 40% vs. 27.2% (HR 1.67, p=0.061), none reaching conventional significance. Both organ-specific (hepatitis, hypothyroidism) and composite irAE endpoints were comparable in both groups. Event counts were too low to be analysable for other organ-specific irAEs. Over a 10-year follow-up, the risk for total SPMs was identical (HR 0.96, p=0.870). However, secondary lymphoproliferative disorders had a non-significant higher trend in the HIV cohort, with a shorter median time-to-onset (355 vs. 762 days; HR 1.40, p=0.225). Conclusion: ICI therapy in PWH with cHL demonstrated a safety profile comparable to HIV-negative patients, with no significant differences observed in the risk of severe cytopenias, opportunistic infections, irAEs, or SPMs. These real-world findings support the safety of ICIs for this underrepresented population. Dedicated prospective trials in PWH are now needed to validate these findings and establish formal safety guidelines.

Dhruv Dhiren Mistry, MBBS: No relevant conflicts of interest to declare.